Wang Qing, Yu Yushuai, Ruan Liqiong, Huang Mingyao, Chen Wei, Sun Xiaomei, Liu Jun, Jiang Zirong
Fujian Medical University, Fuzhou, 350011, China.
Department of Clinical Laboratory, Ningde Municipal Hospital of Ningde Normal University, Ningde, 352100, China.
Cancer Cell Int. 2025 Mar 27;25(1):119. doi: 10.1186/s12935-025-03750-w.
Tumor-associated macrophages (TAMs) are pivotal components of the breast cancer (BC) tumor microenvironment (TME), significantly influencing tumor progression and response to therapy. However, the heterogeneity and specific roles of TAM subpopulations in BC remain inadequately understood.
We performed an integrated analysis of single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (RNA-seq) data from BC patients to comprehensively characterize TAM heterogeneity. Utilizing the MetaTiME computational framework and consensus clustering, we identified distinct TAM subtypes and assessed their associations with clinical outcomes and treatment responses. A machine learning-based predictive model was developed to evaluate the prognostic significance of TAM-related gene expression profiles.
Our analysis revealed three distinct TAM subgroups. Notably, we identified a novel macrophage subtype, M_Macrophage-SPP1-C1Q, characterized by high expression of SPP1 and C1QA, representing an intermediate differentiation state with unique proliferative and oncogenic properties. High infiltration of M_Macrophage-SPP1-C1Q was significantly associated with poor overall survival (OS) and chemotherapy resistance in BC patients. We developed a Random Forest (RF)-based predictive model, Macro.RF, which accurately stratified patients based on survival outcomes and chemotherapy responses, independent of established prognostic parameters.
This study uncovers a previously unrecognized TAM subtype that drives poor prognosis in BC. The identification of M_Macrophage-SPP1-C1Q enhances our understanding of TAM heterogeneity within the TME and offers a novel prognostic biomarker. The Macro.RF model provides a robust tool for predicting clinical outcomes and guiding personalized treatment strategies in BC patients.
肿瘤相关巨噬细胞(TAM)是乳腺癌(BC)肿瘤微环境(TME)的关键组成部分,对肿瘤进展和治疗反应有显著影响。然而,BC中TAM亚群的异质性和特定作用仍未得到充分理解。
我们对BC患者的单细胞RNA测序(scRNA-seq)和批量RNA测序(RNA-seq)数据进行了综合分析,以全面表征TAM的异质性。利用MetaTiME计算框架和一致性聚类,我们确定了不同的TAM亚型,并评估了它们与临床结果和治疗反应的关联。开发了一种基于机器学习的预测模型,以评估TAM相关基因表达谱的预后意义。
我们的分析揭示了三个不同的TAM亚组。值得注意的是,我们鉴定出一种新的巨噬细胞亚型,即M_巨噬细胞-SPP1-C1Q,其特征是SPP1和C1QA高表达,代表具有独特增殖和致癌特性的中间分化状态。M_巨噬细胞-SPP1-C1Q的高浸润与BC患者的总生存期(OS)差和化疗耐药显著相关。我们开发了一种基于随机森林(RF)的预测模型Macro.RF,该模型可根据生存结果和化疗反应准确地对患者进行分层,独立于既定的预后参数。
本研究发现了一种先前未被认识的TAM亚型,它导致BC预后不良。M_巨噬细胞-SPP1-C1Q的鉴定增强了我们对TME内TAM异质性的理解,并提供了一种新的预后生物标志物。Macro.RF模型为预测BC患者的临床结果和指导个性化治疗策略提供了一个强大的工具。